R. Devillier

发表

NKp46 expression on NK cells as a prognostic and predictive biomarker for response to allo-SCT in patients with AML

D. Olive, D. Blaise, A. Toubert, 2017, Oncoimmunology.

Mutations in ASXL1 are associated with poor prognosis across the spectrum of malignant myeloid diseases

D. Birnbaum, R. Devillier, V. Gelsi-Boyer, 2012, Journal of Hematology & Oncology.

Thiotepa, Fludarabine, and Busulfan Conditioning Regimen before T Cell-Replete Haploidentical Transplantation with Post-Transplant Cyclophosphamide for Acute Myeloid Leukemia: A Bicentric Experience of 100 Patients.

D. Blaise, Wang LiNing, R. Devillier, 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

The calcineurin inhibitor and the intensity of the conditioning regimen may affect the occurrence of polyomavirus-associated hemorrhagic cystitis after haploidentical hematopoietic stem cell transplantation with post-transplant cyclophosphamide

D. Blaise, R. Devillier, S. Harbi, 2017, Bone Marrow Transplantation.

Endowing universal CAR T-cell with immune-evasive properties using TALEN-gene editing

P. Duchateau, D. Olive, R. Galetto, 2021, Nature Communications.

TLI in refractory chronic GVHD

D. Blaise, R. Devillier, L. Castagna, 2013, Bone Marrow Transplantation.

T-replete haploidentical allogeneic transplantation using post-transplantation cyclophosphamide in advanced AML and myelodysplastic syndromes

D. Blaise, C. Carlo-Stella, R. Devillier, 2016, Bone Marrow Transplantation.

Brentuximab vedotin followed by allogeneic transplantation as salvage regimen in patients with relapsed and/or refractory Hodgkin's lymphoma

R. Bouabdallah, B. Chetaille, D. Blaise, 2014, Hematological oncology.

Improved outcome of patients with low‐ and intermediate‐risk cytogenetics acute myeloid leukemia (AML) in first relapse with gemtuzumab and cytarabine versus cytarabine

B. Esterni, D. Blaise, R. Devillier, 2011, Cancer.

Non-myeloablative conditioning regimen before T-cell replete haploidentical transplantation with post-transplant cyclophosphamide for advanced Hodgkin's and non-Hodgkin's lymphomas.

A. Santoro, D. Blaise, C. Carlo-Stella, 2020, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Checkpoint inhibition before haploidentical transplantation with posttransplant cyclophosphamide in Hodgkin lymphoma.

R. Bouabdallah, A. Santoro, D. Blaise, 2020, Blood advances.

Immune checkpoints inhibitors for solid tumours after allogeneic haematopoietic stem-cell transplantation: About four clinical cases.

R. Devillier, J. Monnier, C. Gaudy-Marqueste, 2017, European journal of cancer.

Tandem autologous-haploidentical transplantation is a feasible and effective program for refractory Hodgkin lymphoma

A. Santoro, D. Blaise, C. Carlo-Stella, 2018, Bone Marrow Transplantation.

Array comparative genomic hybridization and sequencing of 23 genes in 80 patients with myelofibrosis at chronic or acute phase

D. Birnbaum, R. Devillier, J. Rey, 2014, Haematologica.

Physicians Poster Sessions

R. Bouabdallah, D. Blaise, L. Giordano, 2016, Bone Marrow Transplantation.

Hepatic haemophagocytosis in haematology patients with hepatic dysfunction: prognostic impact and contribution of liver biopsy combined with the haemophagocytic syndrome diagnostic score (HScore)

L. Galicier, R. Devillier, N. Vey, 2022, British journal of haematology.

Acute myeloid leukemia with myelodysplasia‐related changes are characterized by a specific molecular pattern with high frequency of ASXL1 mutations

D. Birnbaum, R. Devillier, N. Vey, 2012, American journal of hematology.

Allogeneic stem cell transplantation in poor prognosis peripheral T-cell lymphoma: the impact of different donor type on outcome

R. Bouabdallah, A. Santoro, D. Blaise, 2020, Bone Marrow Transplantation.

Outcomes of Hodgkin lymphoma patients who relapse after allogeneic stem cell transplantation

R. Bouabdallah, A. Santoro, D. Blaise, 2016, Bone Marrow Transplantation.

Comparison of 60 or 90 mg/m2 of daunorubicin in induction therapy for acute myeloid leukemia with intermediate or unfavorable cytogenetics

D. Blaise, C. Récher, R. Devillier, 2015, American journal of hematology.

Chemotherapy or Allogeneic Stem Cell Transplantation as Salvage Therapy for Patients with Refractory Acute Myeloid Leukemia: A Multicenter Analysis

D. Blaise, Jiong Hu, R. Devillier, 2022, Acta Haematologica.

Prognostic significance of myelodysplasia‐related changes according to the WHO classification among ELN‐intermediate‐risk AML patients

D. Blaise, R. Devillier, J. Rey, 2015, American journal of hematology.

Induction Therapy For AML Patients With Daunorubicin Dose Of 60 Mg/m² and 90 Mg/m² Results In Similar Complete Response Rate, Relapse-Free and Overall Survival

C. Récher, R. Devillier, N. Vey, 2013 .

Haploidentical Allogeneic Hematopoietic Cell Transplantation for Multiple Myeloma Using Post-Transplantation Cyclophosphamide Graft-versus-Host Disease Prophylaxis.

D. Blaise, R. Devillier, M. Marcatti, 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

The new refined minnesota risk score for acute graft-versus-host disease predicts overall survival and non-relapse mortality after T cell-replete haploidentical stem cell transplant with post-transplant cyclophosphamide

A. Santoro, D. Blaise, C. Carlo-Stella, 2019, Bone Marrow Transplantation.

Reduced intensity versus non-myeloablative conditioning regimen for haploidentical transplantation and post-transplantation cyclophosphamide in complete remission acute myeloid leukemia: a study from the ALWP of the EBMT

M. Labopin, I. Yakoub-Agha, D. Blaise, 2022, Bone Marrow Transplantation.

T-cell-replete haploidentical transplantation in acute myeloid leukemia.

D. Blaise, R. Devillier, N. Vey, 2017, Experimental hematology.

Tandem autologous-allogeneic stem cell transplantation as a feasible and effective procedure in high-risk lymphoma patients

R. Bouabdallah, A. Santoro, D. Blaise, 2015, Haematologica.

Function of the Asxl1 Protein

D. Birnbaum, R. Devillier, V. Gelsi-Boyer, 2022 .

Impact of second-degree related donor on the outcomes of T cell-replete haploidentical transplantation with post-transplant cyclophosphamide

R. Fanin, P. Chiusolo, A. Santoro, 2022, Bone Marrow Transplantation.

Combination therapy with ruxolitinib plus intensive treatment strategy is feasible in patients with blast‐phase myeloproliferative neoplasms

H. Dombret, M. Robin, T. Cluzeau, 2016, British journal of haematology.

Posttransplantation cyclophosphamide vs. antithymocyte globulin as GVHD prophylaxis for mismatched unrelated hematopoietic stem cell transplantation

R. Bouabdallah, D. Blaise, R. Devillier, 2019, Bone Marrow Transplantation.

T-Cell Replete Haploidentical Transplantation

D. Blaise, R. Devillier, L. Castagna, 2019, Hematopoietic Cell Transplantation for Malignant Conditions.

HLA-Matched Sibling versus Unrelated versus Haploidentical Related Donor Allogeneic Hematopoietic Stem Cell Transplantation for Patients Aged Over 60 Years with Acute Myeloid Leukemia: A Single-Center Donor Comparison.

D. Blaise, R. Devillier, S. Harbi, 2018, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Donor lymphocyte infusions after haploidentical stem cell transplantation with PTCY: A study on behalf of the EBMT cellular therapy & immunobiology working party

R. Devillier, C. Chabannon, L. Castagna, 2022, Bone Marrow Transplantation.

Successful treatment of post-transplant Epstein–Barr virus-related meningoencephalitis by intravenous rituximab monotherapy

D. Blaise, C. Oudin, R. Devillier, 2012, Leukemia & lymphoma.

Myeloid malignancies: mutations, models and management

D. Birnbaum, R. Devillier, V. Gelsi-Boyer, 2012, BMC Cancer.

Cost-effectiveness analysis of haploidentical vs matched unrelated allogeneic hematopoietic stem cells transplantation in patients older than 55 years

D. Blaise, R. Touzani, R. Devillier, 2018, Bone Marrow Transplantation.

Poor outcome with nonmyeloablative conditioning regimen before cord blood transplantation for patients with high-risk acute myeloid leukemia compared with matched related or unrelated donor transplantation.

D. Blaise, R. Devillier, S. Harbi, 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

The efficacy and safety of a new reduced-toxicity conditioning with 4 days of once-daily 100 mg/m2 intravenous busulfan associated with fludarabine and antithymocyte globulins prior to allogeneic stem cell transplantation in patients with high-risk myelodysplastic syndrome or acute leukemia

D. Blaise, R. Devillier, S. Harbi, 2016, Leukemia & lymphoma.

Allogeneic hematopoietic SCT and mechanical heart valve: feasibility of reduced toxicity myeloablative conditioning

D. Blaise, R. Devillier, N. Vey, 2010, Bone Marrow Transplantation.

Impact of Pretransplant Donor and Recipient Cytomegalovirus Serostatus on Outcome for Multiple Myeloma Patients Undergoing Reduced Intensity Conditioning Allogeneic Stem Cell Transplantation

R. Bouabdallah, D. Blaise, R. Devillier, 2012, Mediterranean journal of hematology and infectious diseases.

Manufacturing Natural Killer Cells as Medicinal Products

Eric Vivier, Christian Chabannon, D. Blaise, 2016, Front. Immunol..

Constitutive AKT activation in follicular lymphoma

R. Bouabdallah, L. Xerri, D. Olive, 2014, BMC Cancer.

Targeting CISH enhances natural cytotoxicity receptor signaling and reduces NK cell exhaustion to improve solid tumor immunity

D. Olive, N. Huntington, J. Nunès, 2021, Journal for ImmunoTherapy of Cancer.

Immune signature drives leukemia escape and relapse after hematopoietic cell transplantation

G. Tonon, E. Stupka, D. Lazarević, 2019, Nature Medicine.

Reduced post-transplant cyclophosphamide doses in haploidentical hematopoietic cell transplantation for elderly patients with hematological malignancies

D. Blaise, M. Mohty, S. Ederhy, 2022, Bone Marrow Transplantation.

Lower Relapse and Better PFS Among Chemosensitive Patients Undergoing Allogeneic Transplantation By Haploidentical Compared With HLA-Identical DONOR: Results On A Cohort Of 94 Patients With Hodgkin’S Lymphoma

R. Bouabdallah, A. Santoro, D. Blaise, 2013 .

T Cell-Replete Haploidentical Transplantation with Post-Transplantation Cyclophosphamide for Hodgkin Lymphoma Relapsed after Autologous Transplantation: Reduced Incidence of Relapse and of Chronic Graft-versus-Host Disease Compared with HLA-Identical Related Donors.

R. Bouabdallah, A. Santoro, D. Blaise, 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Haploidentical transplantation with post-infusion cyclophosphamide in advanced Hodgkin lymphoma

R. Bouabdallah, A. Santoro, D. Blaise, 2017, Bone Marrow Transplantation.

Haploidentical related donor compared to HLA-identical donor transplantation for chemosensitive Hodgkin lymphoma patients

R. Bouabdallah, A. Santoro, D. Blaise, 2020, BMC Cancer.

M. Bernard, P. Chevallier, I. Yakoub-Agha, 2016, Haematologica.

Role of ASXL1 and TP53 mutations in the molecular classification and prognosis of acute myeloid leukemias with myelodysplasia-related changes

D. Birnbaum, C. Récher, C. Demur, 2015, Oncotarget.

A matched‐pair analysis reveals marginally reduced CD34+ cell mobilization on second occasion in 27 related donors who underwent peripheral blood stem cell collection twice at the same institution

D. Blaise, R. Devillier, S. Harbi, 2019, Transfusion.

Haploidentical T Cell-Replete Transplantation with Post-Transplantation Cyclophosphamide for Patients in or above the Sixth Decade of Age Compared with Allogeneic Hematopoietic Stem Cell Transplantation from an Human Leukocyte Antigen-Matched Related or Unrelated Donor.

R. Bouabdallah, D. Blaise, R. Devillier, 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Impact of second-degree related donor on the outcomes of T cell-replete haploidentical transplantation with post-transplant cyclophosphamide

R. Fanin, P. Chiusolo, A. Santoro, 2022, Bone Marrow Transplantation.

Incidence of HLA Loss in a Global Multicentric Cohort of Post-Transplantation Relapses: Results from the Hlaloss Collaborative Study

D. Lazarević, D. Blaise, A. Nagler, 2018, Blood.

Two days of antithymocyte globulin are associated with a reduced incidence of acute and chronic graft‐versus‐host disease in reduced‐intensity conditioning transplantation for hematologic diseases

R. Bouabdallah, B. Esterni, D. Blaise, 2013, Cancer.

Post-transplantation cyclophosphamide-based haploidentical versus Atg-based unrelated donor allogeneic stem cell transplantation for patients younger than 60 years with hematological malignancies: a single-center experience of 209 patients

R. Bouabdallah, D. Blaise, R. Devillier, 2018, Bone Marrow Transplantation.

Impact of antithymocyte globulin doses in reduced intensity conditioning before allogeneic transplantation from matched sibling donor for patients with acute myeloid leukemia: a report from the acute leukemia working party of European group of Bone Marrow Transplantation

J. Bourhis, G. Mufti, F. Baron, 2018, Bone Marrow Transplantation.

Impact of Adding Antithymocyte Globulin to Posttransplantation Cyclophosphamide in Haploidentical Stem-Cell Transplantation.

D. Blaise, M. Mohty, R. Devillier, 2020, Clinical lymphoma, myeloma & leukemia.

The patient’s CMV serological status affects clinical outcome after T-cell replete haplo-HSCT and post-transplant cyclophosphamide

R. Bouabdallah, A. Santoro, D. Blaise, 2016, Bone Marrow Transplantation.

Higher Doses of Antithymocyte Globulin (ATG) Increase the Risk of Relapse in Acute Myeloid Leukemia (AML) Patients Undergoing Matched Related Donor Allogeneic Transplantation in First Complete Remission (CR1): An Analysis from the Acute Leukemia Working Party of EBMT

J. Bourhis, F. Baron, M. Labopin, 2014 .

A conditioning platform based on fludarabine, busulfan, and 2 days of rabbit antithymocyte globulin results in promising results in patients undergoing allogeneic transplantation from both matched and mismatched unrelated donor

R. Bouabdallah, D. Blaise, D. Coso, 2014, American journal of hematology.

Hematopoietic stem cell transplantation for patients with paroxysmal nocturnal hemoglobinuria previously treated with eculizumab: a retrospective study of 21 patients from SFGM-TC centers

P. Chevallier, I. Yakoub-Agha, M. Mohty, 2017, Haematologica.

Reduced-toxicity conditioning prior to allogeneic stem cell transplantation improves outcome in patients with myeloid malignancies

B. Esterni, P. Chevallier, D. Blaise, 2014, Haematologica.

Peripheral blood stem cell for haploidentical transplantation with post-transplant high dose cyclophosphamide: detailed analysis of 181 consecutive patients

R. Bouabdallah, D. Blaise, R. Devillier, 2019, Bone Marrow Transplantation.

Peripheral Blood Stem Cells versus Bone Marrow for T Cell-Replete Haploidentical Transplantation with Post-Transplant Cyclophosphamide in Hodgkin Lymphoma.

R. Bouabdallah, A. Santoro, D. Blaise, 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Clinical outcome of FLAG-IDA chemotherapy sequential with Flu–Bu3 conditioning regimen in patients with refractory AML: a parallel study from Shanghai Institute of Hematology and Institut Paoli-Calmettes

D. Blaise, Jiong Hu, R. Devillier, 2018, Bone Marrow Transplantation.

Donor CD3(+) lymphocyte infusion after reduced intensity conditioning allogeneic stem cell transplantation: single-center experience.

R. Bouabdallah, D. Blaise, C. Oudin, 2013, Experimental hematology.

Antithymocyte globulin in reduced-intensity conditioning regimen allows a high disease-free survival exempt of long-term chronic graft-versus-host disease.

R. Bouabdallah, D. Blaise, C. Oudin, 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

The increase from 2.5 to 5 mg/kg of rabbit anti-thymocyte-globulin dose in reduced intensity conditioning reduces acute and chronic GVHD for patients with myeloid malignancies undergoing allo-SCT

B. Esterni, D. Blaise, R. Devillier, 2012, Bone Marrow Transplantation.

[Haploidentical hematopoietic stem cell transplant: How to choose the best donor? Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)].

P. Chevallier, I. Yakoub-Agha, R. Devillier, 2019, Bulletin du cancer.

Response to immunosuppressive treatment predicts outcome in patients with chronic graft-versus-host disease: a single-center analysis of longitudinal data.

M. Sormani, D. Blaise, C. Oudin, 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Risk Factors for early CMV reactivation and Impact of early CMV reactivation on Clinical Outcomes after T Cell-replete Haploidentical Transplantation with Post-transplant Cyclophosphamide.

A. Santoro, D. Blaise, L. Giordano, 2021, Transplantation and cellular therapy.

Safety of Anti-NKG2A Blocking Antibody Monalizumab As Maintenance Therapy after Allogeneic Hematopoietic Stem Cell Transplantation: A Phase I Study

D. Olive, D. Blaise, A. Chretien, 2021, Blood.

High-dimensional mass cytometry analysis of NK cell alterations in AML identifies a subgroup with adverse clinical outcome

S. Granjeaud, D. Olive, D. Blaise, 2021, Proceedings of the National Academy of Sciences.

High-dimensional mass cytometry analysis of NK cell alterations in Acute Myeloid Leukemia identifies a subgroup with adverse clinical outcome

S. Granjeaud, D. Olive, D. Blaise, 2020, medRxiv.

Low non-relapse mortality and long-term preserved quality of life in older patients undergoing matched related donor allogeneic stem cell transplantation: a prospective multicenter phase II trial

P. Chevallier, D. Blaise, M. Mohty, 2015, Haematologica.

Tacrolimus compared with cyclosporine A after haploidentical T-cell replete transplantation with post-infusion cyclophosphamide

D. Blaise, L. Giordano, C. Carlo-Stella, 2016, Bone Marrow Transplantation.

Prophylactic donor lymphocyte infusions after haploidentical haematopoietic stem cell transplantation for high risk haematological malignancies: a retrospective bicentric analysis of serial infusions of increasing doses of CD3+ cells

D. Blaise, R. Devillier, S. Harbi, 2018, British journal of haematology.

Prophylactic donor lymphocyte infusion after allogeneic stem cell transplantation for high-risk AML

D. Blaise, R. Devillier, S. Harbi, 2017, Bone Marrow Transplantation.

Phase I Trial of Prophylactic Donor-Derived IL-2-Activated NK Cell Infusion after Allogeneic Hematopoietic Stem Cell Transplantation from a Matched Sibling Donor

D. Olive, D. Blaise, R. Devillier, 2020, Cancers.

Haploidentical transplantation with post-infusion cyclophosphamide in advanced Hodgkin lymphoma

R. Bouabdallah, A. Santoro, D. Blaise, 2017, Bone Marrow Transplantation.

In-depth time-dependent analysis of the benefit of allo-HSCT for elderly patients with CR1 AML: a FILO study

P. Chevallier, D. Blaise, M. Béné, 2021, Blood advances.

Killer Cell Immunoglobulin-Like Receptor-Ligand Mismatch in Donor versus Recipient Direction Provides Better Graft-versus-Tumor Effect in Patients with Hematologic Malignancies Undergoing Allogeneic T Cell-Replete Haploidentical Transplantation Followed by Post-Transplant Cyclophosphamide.

D. Blaise, R. Devillier, S. Harbi, 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Positron emission tomography response at the time of autologous stem cell transplantation predicts outcome of patients with relapsed and/or refractory Hodgkin’s lymphoma responding to prior salvage therapy

R. Bouabdallah, A. Santoro, D. Blaise, 2012, Haematologica.

T-Replete Haploidentical Allogeneic Transplantation Using Post-Transplantation Cyclophosphamide in Advanced Acute Myeloid Leukemia and Myelodysplastic Syndromes

A. Santoro, D. Blaise, R. Devillier, 2016 .

Low incidence of chronic GVHD after HLA‐haploidentical peripheral blood stem cell transplantation with post‐transplantation cyclophosphamide in older patients

D. Blaise, R. Devillier, S. Harbi, 2017, British journal of haematology.

Myeloid malignancies: mutations, models and management

Daniel Birnbaum, D. Birnbaum, R. Devillier, 2012, BMC Cancer.

Outcome of relapse after allogeneic stem cell transplant in patients with acute myeloid leukemia

D. Blaise, R. Devillier, J. Rey, 2013, Leukemia & lymphoma.

Mechanisms of NK cell dysfunction in the tumor microenvironment and current clinical approaches to harness NK cell potential for immunotherapy

D. Olive, D. Blaise, R. Devillier, 2020, Journal of leukocyte biology.

Impact of CD34‐positive cell dose on outcome after peripheral blood stem cell allogeneic transplantation prepared with ATG‐based reduced intensity conditioning regimen

D. Blaise, R. Devillier, S. Harbi, 2017, American journal of hematology.

Pooled Allogenic Fecal Microbiotherapy MaaT013 for the Treatment of Steroid-Refractory Gastrointestinal Acute Graft-Versus-Host Disease: Results from the Phase IIa Heracles Study and Expanded Access Program

H. Lanic, P. Chevallier, M. Mohty, 2021, Blood.

Immune signature drives leukemia escape and relapse after hematopoietic cell transplantation

G. Tonon, E. Stupka, D. Lazarević, 2019, Nature Medicine.

Comparative value of post-remission treatment in cytogenetically normal AML subclassified by NPM1 and FLT3-ITD allelic ratio

E. Vellenga, F. Baron, G. Meloni, 2016, Leukemia.

Quantification of Immune Variables from Liquid Biopsy in Breast Cancer Patients Links Vδ2+ γδ T Cell Alterations with Lymph Node Invasion

F. Bertucci, S. Granjeaud, D. Olive, 2021, Cancers.

[Haploidentical hematopoietic stem cell transplant: How to choose the best donor? Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)].

P. Chevallier, I. Yakoub-Agha, R. Devillier, 2020, Bulletin du cancer.

D. Blaise, R. Devillier, S. Harbi, 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

R. Bouabdallah, A. Santoro, D. Blaise, 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Successful and Safe Treatment of Intestinal Graft-Versus-Host Disease (GvHD) with Pooled-Donor Full Ecosystem Microbiota Biotherapeutic: Results from a 29 Patient-Cohort of a Compassionate Use/Expanded Access Treatment Program

M. Mohty, R. Devillier, J. Cornillon, 2020 .

Improved outcome of patients with low‐ and intermediate‐risk cytogenetics acute myeloid leukemia (AML) in first relapse with gemtuzumab and cytarabine versus cytarabine

B. Esterni, D. Blaise, R. Devillier, 2011, Cancer.

GVHD prophylaxis with post-transplant cyclophosphamide results in lower incidence of GVHD and allows faster immunosuppressive treatment reduction compared to antithymocyte globulin in 10/10 HLA-matched unrelated allogeneic hematopoietic cell transplantation

D. Blaise, R. Devillier, S. Harbi, 2023, Bone Marrow Transplantation.

Graft-versus-host disease and relapse/rejection-free survival after allogeneic transplantation for idiopathic severe aplastic anemia: a comprehensive analysis from the SAAWP of the EBMT

A. Ganser, J. Snowden, M. Aljurf, 2023, Haematologica.

R. Bouabdallah, B. Esterni, D. Blaise, 2013, Cancer.

R. Bouabdallah, D. Blaise, R. Devillier, 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.